Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 97

1.

Trisomy 8 in acute myeloid leukemia.

Hemsing AL, Hovland R, Tsykunova G, Reikvam H.

Expert Rev Hematol. 2019 Aug 17. doi: 10.1080/17474086.2019.1657400. [Epub ahead of print]

PMID:
31422708
2.

High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype.

Reikvam H, Aasebø E, Brenner AK, Bartaula-Brevik S, Grønningsæter IS, Forthun RB, Hovland R, Bruserud Ø.

J Clin Med. 2019 Jul 4;8(7). pii: E970. doi: 10.3390/jcm8070970.

3.

Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells.

Nepstad I, Hatfield KJ, Grønningsæter IS, Aasebø E, Hernandez-Valladares M, Hagen KM, Rye KP, Berven FS, Selheim F, Reikvam H, Bruserud Ø.

Signal Transduct Target Ther. 2019 Jun 19;4:20. doi: 10.1038/s41392-019-0050-0. eCollection 2019.

4.

A woman in her forties with pelvic pain and unclear MRI findings.

Brattås MK, Gjelberg HK, Dizdar V, Vetti N, Bertelsen LT, Reikvam H.

Tidsskr Nor Laegeforen. 2019 Apr 24;139(8). doi: 10.4045/tidsskr.18.0541. Print 2019 May 7. Norwegian. No abstract available.

5.

Treatment of acute myeloid leukaemia in elderly patients.

Reikvam H, Dalgaard J, Johansen S, Tvedt THA, Bruserud Ø.

Tidsskr Nor Laegeforen. 2019 Apr 26;139(8). doi: 10.4045/tidsskr.18.0775. Print 2019 May 7. Norwegian.

6.

Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.

Brattås MK, Reikvam H, Tvedt THA, Bruserud Ø.

Expert Opin Investig Drugs. 2019 May;28(5):411-420. doi: 10.1080/13543784.2019.1597052. Epub 2019 Apr 5. Review.

PMID:
30916583
7.

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.

Brattås MK, Lilleeng K, Hovland R, Lægreid IJ, Vorland M, Leh F, Bruserud Ø, Gjertsen BT, Reikvam H.

Biomark Res. 2018 Nov 21;6:33. doi: 10.1186/s40364-018-0147-6. eCollection 2018.

8.

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation.

Reikvam H, Skavland J, Gullaksen SE, Hovland R, Gedde-Dahl T, Bruserud Ø, Gjertsen BT.

Case Rep Hematol. 2018 Sep 23;2018:2045985. doi: 10.1155/2018/2045985. eCollection 2018.

9.

Gelatinøs benmarg.

Hella MNP, Helgeland L, Reikvam H.

Tidsskr Nor Laegeforen. 2018 Sep 12;138(14). doi: 10.4045/tidsskr.18.0296. Print 2018 Sep 18. Norwegian. No abstract available.

10.

Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis.

Nepstad I, Hatfield KJ, Tvedt THA, Reikvam H, Bruserud Ø.

Cancers (Basel). 2018 Sep 14;10(9). pii: E332. doi: 10.3390/cancers10090332.

11.

Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases.

Wendelbo Ø, Opheim EN, Hervig T, Felli Lunde TH, Bruserud Ø, Mollnes TE, Reikvam H.

Vox Sang. 2018 Oct;113(7):657-668. doi: 10.1111/vox.12703. Epub 2018 Aug 29.

PMID:
30159896
12.

Bone marrow abnormalities detected by magnetic resonance imaging as initial sign of hematologic malignancies.

Grønningsæter IS, Ahmed AB, Vetti N, Johansen S, Bruserud Ø, Reikvam H.

Clin Pract. 2018 Jun 7;8(2):1061. doi: 10.4081/cp.2018.1061. eCollection 2018 Mar 28.

13.

Successful eradication of leptomeningeal plasma cell disease.

Bruserud Ø, Hansen BA, Vetti N, Johansen S, Reikvam H.

Oxf Med Case Reports. 2018 Jul 3;2018(7):omy038. doi: 10.1093/omcr/omy038. eCollection 2018 Jul.

14.

Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison.

Nepstad I, Hatfield KJ, Aasebø E, Hernandez-Valladares M, Brenner AK, Bartaula-Brevik S, Berven F, Selheim F, Skavland J, Gjertsen BT, Reikvam H, Bruserud Ø.

Expert Opin Ther Targets. 2018 Jul;22(7):639-653. doi: 10.1080/14728222.2018.1487401. Epub 2018 Jun 22.

PMID:
29889583
15.

Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis.

Mosevoll KA, Johansen S, Wendelbo Ø, Nepstad I, Bruserud Ø, Reikvam H.

Front Med (Lausanne). 2018 May 22;5:147. doi: 10.3389/fmed.2018.00147. eCollection 2018. Review.

16.

Myeloid Sarcoma after Allogenic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients.

Johansen S, Kollsete Gjelberg H, Ahmed AB, Bruserud Ø, Reikvam H.

Case Rep Oncol Med. 2018 Feb 28;2018:7697283. doi: 10.1155/2018/7697283. eCollection 2018.

17.

Inflammatory Mediator Profiles Differ in Sepsis Patients With and Without Bacteremia.

Mosevoll KA, Skrede S, Markussen DL, Fanebust HR, Flaatten HK, Aßmus J, Reikvam H, Bruserud Ø.

Front Immunol. 2018 Apr 6;9:691. doi: 10.3389/fimmu.2018.00691. eCollection 2018.

18.

Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia.

Bartaula-Brevik S, Lindstad Brattås MK, Tvedt THA, Reikvam H, Bruserud Ø.

Expert Opin Investig Drugs. 2018 Apr;27(4):377-387. doi: 10.1080/13543784.2018.1459562. Epub 2018 Apr 4. Review.

PMID:
29611449
19.

The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis.

Melve GK, Ersvaer E, Paulsen Rye K, Bushra Ahmed A, Kristoffersen EK, Hervig T, Reikvam H, Hatfield KJ, Bruserud Ø.

Cytotherapy. 2018 May;20(5):740-754. doi: 10.1016/j.jcyt.2018.02.366. Epub 2018 Mar 22.

PMID:
29576502
20.

Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers.

Reikvam H, Grønningsæter IS, Mosevoll KA, Lindås R, Hatfield K, Bruserud Ø.

Front Immunol. 2018 Jan 24;8:1979. doi: 10.3389/fimmu.2017.01979. eCollection 2017.

Supplemental Content

Loading ...
Support Center